EOF与XELOX方案治疗晚期胃癌的疗效与不良反应比较

    Comparison of EOF and XELOX treatment for advanced g

    • 摘要: 目的:观察奥沙利铂联合表阿霉素、氟尿嘧啶及亚叶酸钙与奥沙利铂联合卡培他滨治疗晚期胃癌的近期疗效和不良反应。方法:晚期胃癌患者75例,采用EOF方案(EOF组)化疗39例,XELOX方案(XELOX组)化疗36例,每3周为1个疗程,均于化疗2个疗程后评价疗效,对比其疗效和不良反应。结果:EOF组总有效率为43.6%,XELOX组总有效率为41.7%,2组间差异无统计学意义(P>0.05)。XELOX组手足综合征发生率明显高于EOF组(P<0.01),但都为Ⅰ、Ⅱ度。EOF组恶心呕吐、骨髓抑制、脱发的发生率均高于XELOX组(P<0.01)。结论:EOF方案和XELOX方案治疗晚期胃癌均有较好的疗效,不良反应均可耐受。XELOX方案用药方便,适合年老体弱的患者,而EOF方案在复治患者中有一定的优势。

       

      Abstract: Objective:To compare the effects and side effects of EOF (oxaliplatin combined with epirubicin and 5-Fluorouacil/leucovorin) with XELOX(oxaliplatin combined with xeloda) in treatment of patients with advanced gastric cancer. Methods:Among 75 patients with advanced gastric cancer,39 cases received EOF treatment and 36 cases received XELOX treatment. The efficacy and toxicity were evaluated after 2 therapy courses. Every therapy course included 3 weeks. Results:The overall effectve rate was 43.6% in EOF group,and 41.7% in XELOX group. There was no significant difference between the two groups(P>0.05). The incidence of hand-foot syndrome in XELOX group was higher than that in EOF group(P<0.01),but that of myelosuppression,nausea,vomiting and alopecie in EOX group higher than that in XEL0X group(P<0.01). Conclusions:The treatment of EOF and XELOX shows well-confirmed effects for advanced gastric cancer. XELOX is more convenient and suitable for the elder or weaker patients,but EOF is more suitable for the recurrent patients.

       

    /

    返回文章
    返回